Lipid Nanoparticle Patents: Who Leads, Where the Gaps Are 2026
Lipid Nanoparticle Formulation Process Patents
22,962 records sit in scope, with filings still concentrated in a peak year of 3,109 in 2022 rather than tapering off. Annual filings rose from 717 in 2017 to a peak of 3,109 in 2022, then held at elevated levels — 2,187 in 2021 climbing to 2,902 in 2024, a 33% increase over that span. Treat 2025 and 2026 figures as provisional; they will revise upward as publications catch up.
- 1MODERNATX INC9.3%
- 2ALNYLAM PHARMACEUTICALS INC4.1%
- 3BIONTECH SE3.9%
- 4INTELLIA THERAPEUTICS INC2.8%
- 5TRANSLATE BIO INC2.7%
See the full lipid nanoparticle formulation process analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
Who holds the most lipid nanoparticle formulation process patents?
The leading assignee holds 2,144 records in this corpus of 22,962, well ahead of the fifth-place holder at 623. The gap between the leader and the rest of the field is large enough that a single company’s portfolio should be the first stop in any freedom-to-operate review. Beyond the top ten, which together hold 31.7% of all records, the ranked list of 100 companies thins into a long tail of smaller and single-filing entrants.
Is the lipid nanoparticle patent field still growing?
Filings rose from 717 in 2017 to a peak of 3,109 in 2022, and the most recent complete comparison — 2,187 filings in 2021 against 2,902 in 2024 — shows a 33% increase. Figures for 2025 and 2026 look lower only because publication lags filing by roughly 18 months; they are not yet complete. Read the trend through 2024 as the reliable signal, not the tail years.
What technology areas dominate lipid nanoparticle formulation patents?
A61K, the medicinal preparations class, appears on 69.6% of the 22,962 records in scope, and C12N, covering microorganisms and genetic engineering, appears on 39.8% — a combination consistent with mRNA and nucleic-acid payload work. Narrower classes like C07H (sugars and nucleic acids, 3.6%) and C12Q (enzyme and DNA testing, 2.8%) mark smaller, more specialised filing activity. Because a single record can carry several IPC classes, these percentages overlap rather than summing to 100%.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Lipid Nanoparticle Formulation Process covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.